Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accumulated Expenses (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Accumulated Expenses data on record, last reported at $7.2 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 54.2% year-over-year to $7.2 million; the TTM value through Sep 2025 reached $7.2 million, down 54.2%, while the annual FY2024 figure was $7.7 million, 36.98% up from the prior year.
  • Accumulated Expenses reached $7.2 million in Q3 2025 per STOK's latest filing, down from $25.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $25.6 million in Q2 2025 and bottomed at $1.5 million in Q1 2023.
  • Average Accumulated Expenses over 4 years is $10.2 million, with a median of $7.7 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: tumbled 86.24% in 2023, then surged 1372.17% in 2025.
  • A 4-year view of Accumulated Expenses shows it stood at $5.8 million in 2022, then fell by 2.49% to $5.6 million in 2023, then soared by 36.98% to $7.7 million in 2024, then dropped by 6.04% to $7.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $7.2 million in Q3 2025, $25.6 million in Q2 2025, and $24.3 million in Q1 2025.